THROMBOCYTOPENIA AS A RISK FACTOR FOR RETINOPATHY OF PREMATURITY

Retina. 2019 Apr;39(4):706-711. doi: 10.1097/IAE.0000000000002028.

Abstract

Purpose: To study the association between thrombocytopenia and retinopathy of prematurity (ROP).

Methods: The case-control study was conducted on preterm newborns with ROP between January 2011 and January 2014, retrospectively. The patients were assigned into two groups: Cases required intervention and controls developed no or Stage I ROP.

Results: Eighty-one premature infants with Type I ROP were enrolled to the study with a mean gestational age of 27.6 ± 2.1 (range: 24-32) weeks and birth weight of 993 ± 292 (range: 560-1,930) g. Mean follow-up time was 38.3 ± 2.7 weeks (min: 32 and max: 46 weeks). Cases were individually matched to a set of controls (1:1 ratio). Thrombocytopenia (<150.000/mm) was seen in 58 (71.6%) of the cases with Type I ROP, whereas only 17 (21%) of the controls had thrombocytopenia (P < 0.001). Logistic regression analysis showed that bronchopulmonary dysplasia and thrombocytopenia were significantly associated with Type I ROP (relative risk [95% confidence interval]: 4.19 [1.47-12] and 6.69 [2.83-15.9], respectively). The thrombocytopenia ratio (P = 0.073), thrombocytopenia 1 week before intervention (P = 0.076) and platelet transfusion ratio (P = 0.062) tended to be higher in Zone I ROP compared with Zone II ROP.

Conclusion: In our study, there was a significant association between thrombocytopenia and Type I ROP.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use
  • Birth Weight
  • Case-Control Studies
  • Female
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intravitreal Injections
  • Laser Coagulation
  • Male
  • Retinopathy of Prematurity / diagnosis
  • Retinopathy of Prematurity / epidemiology*
  • Retinopathy of Prematurity / therapy
  • Retrospective Studies
  • Risk Factors
  • Thrombocytopenia / diagnosis
  • Thrombocytopenia / epidemiology*
  • Thrombocytopenia / therapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab